Scientists have warned that the main drugs being repurposed for COVID-19 could end up being too expensive for many people around the world – unless drugmakers are prepared to s
NICE has published final draft guidance recommending regular NHS funding for Roche’s Kadcyla (trastuzumab emtansine) in its newer use, for certain people with HER2-positive early breast can
England’s NHS should not fund Roche’s Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine for adults with a form of advanced lymphoma, NICE has said in first draft g
NICE’s decision-making process will come under legal scrutiny in court this week, after a child and her family claimed the NHS cost-effectiveness body is unlawfully limiting access to a lif
Shionogi’s Mulpleo for severely low levels of blood platelets caused by liver disease is to be made available to NHS patients across the UK after authorities in England and Scotland said it
AbbVie’s Rinvoq rheumatoid arthritis drug is an important part of the company’s strategy to replace lost sales as its mega-blockbuster Humira finally succumbs to cheaper biosimilar competit